Existing studies have documented that livin protein is overexpressed in many lung cancer cell lines and primary lung cancers and that many patients with lung cancer have anti‐livin antibodies, as well as anti‐livin cellular immune responses,29, 30, 31 hinting the potential of livin as a target for the immunotherapy of lung cancer. This evidence concerns the gene BIRC7 and lung carcinoma.